Corcept Therapeutics Inc. (CORT) - 10-K Summary
Business Context and Reporting Period
Company: Corcept Therapeutics Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: Corcept is a commercial-stage biopharmaceutical company focused on modulating cortisol to treat endocrinologic, oncologic, metabolic, and neurologic disorders. Its primary commercial product is Korlym (mifepristone) for hypercortisolism (Cushing's syndrome). In June 2024, the company launched an authorized generic version of Korlym. The company is advancing a pipeline of proprietary selective cortisol modulators, with relacorilant (for hypercortisolism) having a New Drug Application (NDA) submitted to the FDA in December 2024.
Key Financial Metrics
| Metric (in millions) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net Product Revenue | $675.0 | $482.4 | $401.9 |
| Cost of Sales | $10.9 | $6.5 | $5.4 |
| Gross Margin | 98.4% | 98.7% | 98.7% |
| Research & Development Expense | $246.9 | $184.4 | $131.0 |
| Selling, General & Admin Expense | $280.3 | $184.3 | $152.8 |
| Income from Operations | $137.0 | $107.3 | $112.6 |
| Net Income | $141.2 | $106.1 | $101.4 |
| Diluted EPS | $1.23 | $0.94 | $0.87 |
| Cash, Cash Equivalents & Marketable Securities | $603.2 | $425.4 | N/A |
| Net Cash Provided by Operating Activities | $198.1 | $127.0 | $120.3 |
Note: The filing text does not provide specific long-term debt figures; the company relies on cash reserves and operating cash flow to fund operations.
Material Changes vs. Prior Period
- Revenue Growth: Net product revenue increased 40% year-over-year to $675.0 million. Growth was driven by a 79.4% increase in sales volume and a price increase effective January 1, 2024.
- Expense Increases: R&D expenses rose 34% to $246.9 million due to spending on Cushing's syndrome and oncology development programs. SG&A expenses increased 52% to $280.3 million, primarily due to higher employee compensation and sales/marketing activities.
- Profitability: Net income increased 33% to $141.2 million, driven by higher revenue and interest income ($24.5 million vs. $17.3 million in 2023), partially offset by higher tax expenses.
- Legal Settlement: The company settled the Melucci securities class action litigation for $14 million in 2024, which was fully reimbursed by insurance.
Guidance, Outlook, Risks, and Unusual Items
- Relacorilant NDA: In December 2024, Corcept submitted an NDA to the FDA for relacorilant, a selective cortisol modulator for hypercortisolism, based on positive Phase 3 GRACE and GRADIENT trial data. Approval could grant seven years of U.S. orphan drug exclusivity.
- Generic Competition: Teva launched a generic version of Korlym in January 2024. Corcept is appealing a December 2023 court ruling that found Teva's product did not infringe Corcept's patents. The company also launched its own authorized generic in June 2024.
- Antitrust Litigation: Teva filed an antitrust lawsuit against Corcept and its specialty pharmacy partner, Optime, in June 2024. A separate antitrust complaint was filed by insurance companies in February 2025.
- Government Investigation: The U.S. Attorney's Office for the District of New Jersey is investigating Corcept's sale and promotion of Korlym. The company is cooperating and is not currently considered a defendant.
- IRS/IRA Impact: The Inflation Reduction Act (IRA) imposes new rebates and price negotiation mechanisms that may materially reduce future revenue and profits, particularly starting in 2025.
- Clinical Updates:
- Oncology: Enrollment is complete for the Phase 3 ROSELLA trial (relacorilant + nab-paclitaxel for ovarian cancer).
- ALS: The Phase 2 DAZALS trial for dazucorilant did not meet its primary endpoint, though a survival signal was observed (0 deaths in high-dose arm vs. 5 in placebo).
- MASH: The Phase 2b MONARCH trial for miricorilant is ongoing.
Key Facts for Investor Verification
- Patent Litigation Outcome: Monitor the appeal of the December 2023 district court ruling regarding Teva's generic Korlym infringement, as this directly impacts future revenue protection.
- Relacorilant Approval Timeline: Verify the FDA's review timeline and potential approval date for the relacorilant NDA submitted in December 2024.
- Antitrust Case Status: Track the progress of the Teva antitrust lawsuit and the February 2025 insurance company lawsuit, which allege unfair business practices.
- Government Investigation Resolution: Confirm the status of the New Jersey U.S. Attorney's Office investigation into Korlym promotion and reimbursement practices.
- Revenue Mix: Assess the impact of the authorized generic launch and Teva's generic entry on the net price per tablet and overall volume growth in 2025.